双歧杆菌三联活菌胶囊治疗溃疡性结肠炎的临床观察 点击下载
论文标题： 双歧杆菌三联活菌胶囊治疗溃疡性结肠炎的临床观察
英文标题：
中文摘要： 目的：观察双歧杆菌三联活菌胶囊治疗溃疡性结肠炎（UC）的疗效和安全性。方法：94例UC患者随机均分为对照组和研究组。对照组患者给予营养支持、清淡饮食、5-氨基水杨酸等常规治疗；研究组患者在对照组治疗的基础上加服双歧杆菌三联活菌胶囊420 mg，每日3次。两组患者疗程均为8周。观察两组患者的临床疗效，治疗前后血清D-乳酸、二胺氧化酶（DAO）水平及不良反应发生情况。结果：研究组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）。治疗后，两组患者血清D-乳酸、DAO水平均显著低于治疗前，且研究组低于对照组，差异均有统计学意义（P＜0.05或P＜0.01）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：在常规治疗的基础上，双歧杆菌三联活菌胶囊治疗UC的疗效和安全性均较好。
英文摘要： OBJECTIVE： To observe the efficacy and safety of Bifid triple viable capsule in the treatment of ulcerative colitis （UC）. METHODS： 94 patients with UC were randomly divided into control group and research group. Control groups was given nutrition support， light diet and 5-amino salicylic acid and other conventional treatment； research group was additionally given 420 mg Bifid triple viable capsule， 3 times aday. Treatment course for both group was 8 weeks. The clinical efficacy， and serum D-lactic acid， diamine oxidase （DAO） levels before and after treatment， and incidence of adverse reactions in 2 groups were observed. RESULTS：The total effective rate in research group was significantly higher than control group， the difference was statistically significant（P＜0.05）； after treatment， serum D-lactic acid， DAO levels in 2 groups were significantly lower than before， and research group was lower than control group， the differences were statistically significant（P＜0.05 or P＜0.01）； and there was no significant difference in the incidence of adverse reactions（P＞0.05）. CONCLUSIONS： Based on the conventional treatment， both the efficacy and safety of Bifid triple viable capsule are good in the treatment of UC.
期刊： 2015年第26卷第36期
作者： 毛立新，郭元春，钱剑
英文作者： MAO Li-xin，GUO Yuan-chun，QIAN Jian
关键字： 溃疡性结肠炎；双歧杆菌三联活菌胶囊；肠黏膜屏障；疗效；安全性
KEYWORDS： Ulcerative colitis； Bifid triple viable capsule； Intestinal mucous membrane barrier； Efficacy； Safety
总下载数： 81次
本日下载数： 2次
本月下载数： 81次
文件大小： 619.60Kb

* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！